Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Are Naïve to Targeted Therapies
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary) ; Vedolizumab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms REVAMP
- Sponsors AbbVie
- 24 Mar 2025 New trial record